A MULTICENTER RANDOMIZED STUDY IN EARLY RHEUMATOID ARTHRITIS TO COMPARE ACTIVE CONVENTIONAL THERAPY VERSUS THREE BIOLOGICAL TREATMENTS: 24 WEEK EFFICACY RESULTS OF THE NORD-STAR TRIAL

• Main Authors: Hørslev-Petersen, Kim, Hetland, Merete Lund, Haavardsholm, E. A., Rudin, A., Nordstrom, D., Nurmohamed, M., Gudbjornsson, B, Lampa, J., Uhlig, Till, Gröndal, G., Østergaard, M, Heiberg, M., Twisk, J., Krabbe, S., Lend, K., Olsen, I., Lindqvist, J., Ekwall, A. K. H., Grøn, Kathrine L., Kapetanovic, Meliha C., Faustini, Francesca, Tuompo, Riitta, Lorenzen, Tove, Cagnotto, Giovanni, Baecklund, E, Hendricks, Oliver, Vedder, D., Sokka-isler, Tuulikki, Husmark, Tomas, Ljosa, Maud-Kristine Aga, Brodin, Eli, Ellingsen, Torkell Juulsgaard, Soderbergh, Annika, Rizk, Milad, Reckner, Å., Larsson, P., Uhrenholt, L., Just, S. A., Stevens, David, Laurberg, TB, Bakland, Gunnstein, van Vollenhoven, Ronald F
• Format: Conference Object
• Language: English
• Published: 2020
• Subjects: Norway; Sokka; Iceland
• Online Access: https://portal.findresearcher.sdu.dk/da/publications/57bffce4-1617-49c3-93d6-a33f0065d270

OP0018 (2020) A MULTICENTER RANDOMIZED STUDY IN EARLY RHEUMATOID ARTHRITIS TO COMPARE ACTIVE CONVENTIONAL THERAPY VERSUS THREE BIOLOGICAL TREATMENTS: 24 WEEK EFFICACY RESULTS OF THE NORD-STAR TRIAL M. L. Hetland1, E. A. Haavardsholm1, A. Rudin1, D. Nordström1, M. Nurmohamed1, B. Gudbjornsson1, J. Lampa1, K. Hørslev-Petersen1, T. Uhlig1, G. Gröndal1, M. Ǿstergaard1, M. Heiberg1, J. Twisk1, S. Krabbe1, K. Lend1, I. Olsen1, J. Lindqvist1, A. K. H. Ekwall1, K. L. Grøn1, M. C. Kapetanovic1, F. Faustini1, R. Tuompo1, T. Lorenzen1, G. Cagnotto1, E. Baecklund1, O. Hendricks1, D. Vedder1, T. Sokka-Isler1, T. Husmark1, M. K. A. Ljosa1, E. Brodin1, T. Ellingsen1, A. Soderbergh1, M. Rizk1, Å. Reckner1, P. Larsson1, L. Uhrenholt1, S. A. Just1, D. Stevens1, T. B. Laurberg1, G. Bakland1, R. Van Vollenhoven1 1Denmark, Finland, Iceland, Netherlands, Norway, Sweden Background: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. Objectives: The primary aim was to assess and compare the proportion of pts who achieved remission with active conventional therapy (ACT) and with three different biologic therapies after 24 wks. Secondary aims were to assess and compare other efficacy measures. Methods: The investigator-initiated NORD-STAR trial (NCT01491815) was conducted in the Nordic countries and Netherlands. In this multicenter, randomized, open-label, blinded-assessor study pts with treatment-naïve, early RA with DAS28>3.2, and positive RF or ACPA, or CRP >10mg/L were randomized 1:1:1:1. Methotrexate (25 mg/week after one month) was combined with: 1) (ACT): oral prednisolone (tapered quickly); or : sulphasalazine, hydroxychloroquine and mandatory intra-articular (IA) glucocorticoid (GC) injections in swollen joints <wk 20; 2) certolizumab 200 mg EOW SC (CZP); 3) abatacept 125 mg/wk SC (ABA); tocilizumab 162 mg/wk SC (TCZ). IA GC was allowed in all arms <wk 20. Primary outcome was clinical disease activity index remission (CDAI≤2.8) at wk 24. Secondary outcomes ...